Current and future regenerative medicine-Principles, concepts, and therapeutic use of stem cell therapy and tissue engineering in equine medicine

Canadian Veterinary Journal

Volumn 50, Issue 2, 2009, Pages 155-165

  Koch, Thomas G ^a,b   Berg, Lise C ^b   Betts, Dean H ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANIMAL DISEASE; GRAFT SURVIVAL; HORSE; HORSE DISEASE; PHYSIOLOGY; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TREATMENT OUTCOME; VETERINARY MEDICINE;

ANIMALS; GRAFT SURVIVAL; HORSE DISEASES; HORSES; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING; TREATMENT OUTCOME; VETERINARY MEDICINE;

AVES; EQUIDAE;

EID: 62549132700     PISSN: 00085286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, er al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282: 1145-1147.
2. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells 2001;19:193-204.
3. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
4. Koch TG, Berg LC, Betts DH. Concepts for the clinical use of stem cells in equine medicine. Can Vet J 2008;49:1009-1017.
5. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy Position Statement, Cytotherapy 2006;8: 315-317.
6. Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy Position Statement. Cytotherapy 2005;7:393-395.
7. Gratwohl A, Baldomero H, Frauendorfer K, Rocha V, Apperley J, Niederwieser D. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: Focus on the use of cord blood products. Bone Marrow Transplant 2008;41:687-705.
8. Elisseeff J. Injectable cartilage tissue engineering. Expert Opin Biol Ther 2004;4:1849-1859.
9. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-1826.
10. Charwat S, Gyongyosi M, Lang I, et al. Role of adult bone marrow stem cells in the repair of ischemic myocardium: Current state of the art. Exp Hematol 2008;36:672-680.
11. Ballard VL, Edelberg JM. Stem cells for cardiovascular repair- The challenges of the aging heart. J Mol Cell Cardiol 2008. In press.
12. Izuta Y, Ochi M, Adachi N, Deie M, Yamasaki T, Shinomiya R. Meniscal repair using bone marrow-derived mesenchymal stem cells: Experimental study using green fluorescent protein transgenic rats. Knee 2005;12:217-223.
13. Angele P, Johnstone B, Kujat R, et al. Stem cell based tissue engineering for meniscus repair. J Biomed Mater Res A 2008;85:445-455.
14. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003;48:3464-3474.
15. Kondziolka D, Wechsler L. Stroke repair with cell transplantation: Neuronal cells, neuroprogenitor cells, and stem cells. Neurosurg Focus 2008;24:E13.
16. Kalluri HS, Dempsey RJ. Growth factors, stem cells, and stroke. Neurosurg Focus 2008;24:E14.
17. Guzman R, Choi R, Gera A, De Los Angeles A, Andres RH, Steinberg GK. Intravascular cell replacement therapy for stroke. Neurosurgi Focus 2008;24:E15.
18. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-1084.
19. Sato K, Ozaki K, Oh I, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-234.
20. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150.
21. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007;262:509-525.
22. Keating A. How do mesenchymal stromal cells suppress T cells? Cell Stem Cell 2008;2:106-108.
23. Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007;21:1992-1999.
24. Aksu AE, Horibe E, Sacks J, et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008. In press.
25. Tian Y, Deng YB, Huang YJ, Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest 2008;37:29-42.
26. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007;137:87-98.
27. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: Preliminary study. Equine Vet J 2008;40:178-181.
28. Smith RK, Korda M, Blunn GW, Goodship AE. Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet J 2003;35:99-102.
29. Pacini S, Spinabella S, Trombi L, et al. Suspension of bone marrow- derived undifferentiated mesenchymal stromal cells for repair of superficial digital flexor tendon in race horses. Tissue Eng 2007; 13: 2949-2955.
30. Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model. J Orthop Res 2007;25:913-925.
31. Abdallah BM, Kassem M. Human mesenchymal stem cells: From basic biology to clinical applications. GeneTher 2008;15:109-116.
32. Brooke G, Cook M, Blair C, et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007;18:846-858.
33. Crovace A, Lacitignola L, De Siena R, Rossi G, Francioso E. Cell therapy for tendon repair in horses: An experimental study. Vet Res Commun 2007;31 Suppl 1:281-283.
34. Blatt A, Cotter G, Leitman M, et al. Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. Am Heart J 2005; 150: 986.el-986.e7.
35. Beeres SL, Lamb HJ, Roes SD, et al. Effect of intramyocardial bone marrow cell injection on diastolic function in patients with chronic myocardial ischemia. J Magn Reson Imaging 2008;27:992-997.
36. Bartsch T, Brehm M, Zeus T, Strauer BE. Autologous mononuclear stem cell transplantation in patients with peripheral occlusive arterial disease. J Cardiovasc Nurs 2006;21:430-432.
37. Schafer R, Wiskirchen J, Guo K, et al. Aptamer-based isolation and subsequent imaging of mesenchymal stem cells in ischemic myocard by magnetic resonance imaging. Rofo 2007;179:1009-1015.
38. Oertel M, Menthena A, Chen YQ, Teisner B, Jensen CH, Shafritz DA. Purification of fetal liver stem/progenitor cells containing all the repopulation potential for normal adult rat liver. Gastroenterology 2008;134:823-832.
39. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-1301.
40. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006;5:91-116.
41. Kassem M, Kristiansen M, Abdallah BM. Mesenchymal stem cells: Cell biology and potential use in therapy. Basic Clin Pharmacol Toxicol 2004;95:209-214.
42. Hu X, Wang J, Chen J, et al. Optimal temporal delivery of bone marrow mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007;31:438-443.
43. Carstanjen B, Desbois C, Hekmati M, Behr L. Successful engraftment of cultured autologous mesenchymal stem cells in a surgically repaired soft palate defect in an adult horse. Can J Vet Res 2006; 70:143-147.
44. Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol 2007;7:26.
45. Reed SA, Johnson SE. Equine umbilical cord blood contains a population of stem cells that express Oct4 and differentiate into mesodermal and endodermal cell types. J Cell Physiol 2008;215:329-336.
46. Giovannini S, Brehm W, Mainil-Varlet P, Nesic D. Multilineage differentiation potential of equine blood-derived fibroblast-like cells. Differentiation 2008;76:118-129.
47. Stewart AA, Byron CR, Pondenis H, Stewart MC. Effect of fibroblast growth factor-2 on equine mesenchymal stem cell monolayer expansion and chondrogenesis. Am J Vet Res 2007;68:941-945.
48. Kisiday JD, Kopesky PW, Evans CH, Grodzinsky AJ, McIlwraith CW, Frisbie DD. Evaluation of adult equine bone marrow- and adipose- derived progenitor cell chondrogenesis in hydrogel cultures. J Orthop Res 2008;26:322-331.
49. Koerner J, Nesic D, Romero JD, Brehm W, Mainil-Varlet P, Grogan SP. Equine peripheral blood-derived progenitors in comparison to bone marrow-derived mesenchymal stem cells. Stem Cells 2006;24:1613-1619.
50. Fortier LA, Nixon AJ, Williams J, Cable CS. Isolation and chondrocytc differentiation of equine bone marrow-derived mesenchymal stem cells. Am J Vet Res 1998;59:1182-1187.
51. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies. Mech Ageing Dev 2008;129:163-173.
52. Bonyadi M, Waldman SD, Liu D, Aubin JE, Grynpas MD, Stanford WL. Mesenchymal progenitor self-renewal deficiency leads to age- dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci USA 2003;100:5840-5845.
53. Yoo JU, Johnstone B. The role of osteochondral progenitor cells in fracture repair. Clin Orthop Relat Res 1998:355 Suppl:S73-81.
54. Kraus KH, Kirker-Head C. Mesenchymal stem cells and bone regeneration. Vet Surg 2006;35:232-242.
55. O'Rielly JL, Bertone AL, Genovese RL. Treatment of a chronic comminuted fracture of the fibula in a horse. J Am Vet Med Assoc 1998; 212:396-398.
56. Lescun TB, Morisset SM, Fugaro MN, Blevins WE. Facilitated ankylosis of the distal interphalangeal joint in a foal. Aust Vet J 2004;82: 282-285.
57. Harriss FK, Galuppo LD, Decock HE, McDuffee LA, Macdonald MH. Evaluation of a technique for collection of cancellous bone graft from the proximal humerus in horses. Vet Surg 2004;33:293-300.
58. McDuffee LA, Anderson GI. In vitro comparison of equine cancellous bone graft donor sites and tibial periosteum as sources of viable osteoprogenitors. Vet Surg 2003;32:455-463.
59. McDuffee LA, Anderson GI, Wrighr GM, Ryan DA. In vitro heterogeneity of osteogenic cell populations at various equine skeletal sites. Can J Vet Res 2006;70:277-284.
60. Hoynowski SM, Fry MM, Gardner BM, et al. Characterization and differentiation of equine umbilical cord-derived matrix cells. Biochem Biophys Res Commun 2007;362:347-353.
61. Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. Characterization of equine adipose tissue-derived stromal cells: Adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg 2007;36:613-622.
62. Vidal MA, Kilroy GE, Johnson JR, Lopez MJ, Moore RM, Gimble JM. Cell growth characteristics and differentiation frequency of adherent equine bone marrow-derived mesenchymal stromal cells: Adipogenic and osteogenic capacity. Vet Surg 2006;35:601-610.
63. Arnhold SJ, Goletz I, Klein H, et al. Isolation and characterization of bone marrow-derived equine mesenchymal stem cells. Am J Vet Res 2007;68:1095-1105.
64. Engel E, Michiatdi A, Navarro M, Lacroix D, Planell JA. Nanotechnology in regenerative medicine: The materials side. Trends Biotechnol 2008;26:39-47.
65. Arumuganathar S, Jayasinghe SN. Living scaffolds (specialized and unspecialized) for regenerative and therapeutic medicine. Biomacromolecules 2008;9:759-766.
66. Hutmacher DW, Cool S. Concepts of scaffold-based tissue engineering - the rationale to use solid free-form fabrication techniques. J Cell Mol Med 2007;11:654-669.
67. Hutmacher DW, Schantz JT, Lam CX, Tan KC, Lim TC. State of the art and future directions of scaffold-based bone engineering from a biomaterials perspective. J Tissue Eng Regen Med 2007;1:245-260.
68. Bonfield W. Designing porous scaffolds for tissue engineering. Philos Transact A Math Phys Eng Sci 2006;364:227-232.
69. Raghunath J, Rollo J, Sales KM, Butler PE, Seifalian AM. Biomaterials and scaffold design: Key to tissue-engineering cartilage. Biotechnol Appl Biochem 2007;46:73-84.
70. Ko HC, Milthorpe BK, McFarland CD. Engineering thick tissues - the vascularisation problem. Eur Cell Mater 2007;14:18-19.
71. Lynn AK, Brooks RA, Bonfield W, Rushton N. Repair of defects in articular joints. Prospects for material-based solutions in tissue engineering. J Bone Joint Surg Br 2004;86:1093-1099.
72. Tognana E, Borrione A, De Luca C, Pavesio A. Hyalograft C: hyaluronanbased scaffolds in tissue-engineered cartilage. Cells Tissues Organs 2007;186:97-103.
73. Badylak SF, Vorp DA, Spievack AR, et al. Esophageal reconstruction with ECM and muscle tissue in a dog model. J Surg Res 2005;128: 87-97.
74. Badylak SF, Kochupura PV, Cohen IS, et al. The use of extracellular matrix as an inductive scaffold for the partial replacement of functional myocardium. Cell Transplant 2006; 15 Suppl LS29-40.
75. Brennan EP, Reing J, Chew D, Myers-Irvin JM, Young EJ, Badylak SF. Antibacterial activity within degradation products of biological scaffolds composed of extracellular marrix. Tissue Eng 2006;12: 2949-2955.
76. Badylak SF. Extracellular matrix as a scaffold for tissue engineering in veterinary medicine: Applications to soft tissue healing. Clin Tech Equine Pract 2004;3:173-181.
77. Shu XZ, Liu Y, Palumbo F, Prestwich GD. Disulfide-crosslinked hyaluronan-gelatin hydrogel films: A covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 2003;24:3825-3834.
78. Kirker KR, Luo Y, Morris SE, Shelby J, Presrwich GD. Glycosaminoglycan hydrogels as supplemental wound dressings for donor sites. J Burn Care Rehabil 2004;25:276-286.
79. Eingartner C. Current trends in total hip arthroplasty. Orthop Traumatol Rehabil 2007;9:8-14.
80. Breusch SJ, Lukoschek M, Thomsen M, Mau H, Ewerbeck V, Aldinger PR. Ten-year results of uncemented hip stems for failed intertrochanteric osteotomy. Arch Orrhop Trauma Surg 2005;125: 304-309.
81. Parsch D, Jung AW, Thomsen M, Ewerbeck V, Aldinger PR. Good survival of uncemented tapered stems for failed intertrochanteric osteotomy: A mean 16 year follow-up study in 45 patients. Arch Orthop Trauma Surg 2007. In press.
82. Eingartner C, Heigele T, Dieter J, Winter E, Weise K. Long-term tesults with the BiCONTACT system-aspects to investigate and to learn from. Int Orthop 2003;27 Suppl 1:S11-15.
83. Mikos AG, Herring SW, Ochareon P, et al. Engineering complex tissues. Tissue Eng 2006;12:3307-3339.
84. Pilliar RM, Kandel RA, Grynpas MD, Zalzal P, Hurtig M. Osteochondral defect repair using a novel tissue engineering approach: Sheep model srudy. Technol Health Care 2007;15:47-56.
85. Kandel RA, Grynpas M, Pilliar R, et al. Repair of osteochondral defects with biphasic cartilage-calcium polyphosphate constructs in a sheep model. Biomaterials 2006;27:4120-4131.
86. Bodo G, Hangody L, Modis L, Hurtig M. Autologous osteochondral grafting (mosaic arthroplasty) for treatment of subchondral cystic lesions in the equine stifle and fetlock joints. Vet Surg 2004;33:588-596.
87. Huang KY, Yan JJ, Hsieh CC, Chang MS, Lin RM. The in vivo biological effects of intradiscal recombinant human bone morphogenetic protein-2 on the injured intervertebral disc: An animal experiment. Spine 2007;32:1174-1180.
88. Hamilton DK, Jones-Quaidoo SM, Sansur C, Shaffrey CI, Oskouian R, Jane JA, Sr. Outcomes of bone morphogenetic protein-2 in mature adults: Posterolateral non-instrument-assisted lumbar decompression and fusion. Surg Neurol 2008;69:457-461.
89. DiPaola CP, Molinari RW. Posterior lumbar interbody fusion. J Am Acad Orthop Surg 2008;16:130-139.
90. Hollinger JO, Hart CE, Hirsch SN, Lynch S, Friedlaender GE. Recombinant human platelet-derived growth factor: Biology and clinical applications. J Bone Joint Surg Am 2008;90 Suppl 1:48-54.
91. Rocchietta I, Dellavia C, Nevins M, Simion M. Bone regenerated via rh PDGF-bB and a deproteinized bovine bone matrix: Backscattered electron microscopic element analysis. Int J Periodontics Restorative Dent 2007;27:539-545.
92. Schnabel LV, Mohammed HO, Miller BJ, et al. Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor digitorum superficialis tendons. J Orthop Res 2007;25:230-240.
93. Smirh JJ, Ross MW, Smith RK. Anabolic effects of acellular bone marrow, platelet rich plasma, and serum on equine suspensory ligament fibroblasts in vitro. Vet Comp Orthop Traumatol 2006;19:43-47.
94. Schnabel LV, Sonea HO, Jacobson MS, Fortier LA. Effects of platelet rich plasma and acellular bone marrow on gene expression patterns and DNA content of equine suspensory ligament explant cultures. Equine Vet J 2008;40:260-265.
95. Dahlgren LA, van der Meulen MC, Berrram JE, Starrak GS, Nixon AJ. Insulin-like growth factor-I improves cellular and molecular aspects of healing in a collagenase-induced model of flexor tendinitis. J Orthop Res 2002;20:910-919.
96. Hoffmann A, Pelled G, Turgeman G, et al. Neotendon formation induced by manipulation of the Smad8 signalling pathway in mesenchymal stem cells. J Clin Invest 2006;116:940-952.
97. Towler DA, Gelberman RH. The alchemy of tendon repair: A primer for the (S)mad scientist. J Clin Invest 2006;116:863-866.
98. Asian H, Kimelman-Bleich N, Pelled G, Gazit D. Molecular targets for tendon neoformation. J Clin Invest 2008;118:439-444.
99. Fortier LA, Smith RK. Regenerative medicine for tendinous and ligamentous injuries of sport horses. Vet Clin North Am Equine Pract 2008;24:191-201.
100. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. J Bone Joint Surg Br 2007;89:672-685.
101. Frisbie DD, Mcllwrairh CW. Gene therapy: Future therapies in osteoarthritis. Ver Clin North Am Equine Ptact 2001; 17:233-243.
102. Morisset S, Frisbie DD, Robbins PD, Nixon AJ, Mcllwraith CW. IL-1ra/IGF-1 gene therapy modulates repair of microfractured chondral defects. Clin Orthop Relat Res 2007;462:221-228.
103. Goodrich LR, Brower-Toland BD, Warnick L, Robbins PD, Evans CH, Nixon AJ. Direct adenovirus-mediated IGF-I gene transduction of synovium induces persisting synovial fluid IGF-I ligand elevations. Gene Thet 2006;13:1253-1262.
104. Nixon AJ, Brower-Toland BD, Bent SJ, et al. Insulinlike growth factor-I gene therapy applications for cartilage repair. Clin Orthop Relat Res 2000;379 Suppl: S201-213.
105. Frisbie DD, Mcllwraith CW. Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clin Orthop Relat Res 2000:379 Suppl: S273-287.
106. Brower-Toland BD, Saxer RA, Goodrich LR, et al. Direct adenovirus- mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. Hum Gene Ther 2001;12:117-129.
107. Saxer RA, Bent SJ, Brower-Toland BD, et al. Gene mediated insulinlike growth factor-I delivery to the synovium. J Orthop Res 2001;19: 759-767.
108. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, Mcllwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9:12-20.
109. Nixon AJ, Haupt JL, Frisbie DD, et al. Gene-mediated restoration of cartilage matrix by combination insulin-like growth factor-I/interleukin-1 receptor antagonist therapy. Gene Ther 2005;12: 177-186.
110. Haupt JL, Frisbie DD, Mcllwraith CW, et al. Dual transduction of insulin-like growth factor-I and inrerleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res 2005;23:118-126.
111. Strauss EJ, Goodrich LR, Chen CT, Hidaka C, Nixon AJ. Biochemical and biomechanical properties of lesion and adjacent articular cartilage after chondral defect repair in an equine model. Am J Sports Med 2005;33:1647-1653.
112. Ishihara A, Zachos TA, Bartlett JS, Bertone AL. Evaluation of permissiveness and cytotoxic effects in equine chondrocytes, synovial cells, and stem cells in response to infection with adenovirus 5 vectors for gene delivery. Am J Vet Res 2006;67:1145-1155.
113. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectots in animals and humans: A continued challenge. Gene Ther 2008; 15:808-816.
114. Bauer G, Dao MA, Case SS, et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol Ther 2008;16:1308-1315.
115. Brown PA, Bodles-Brakhop A, Draghia-Akli R. Plasmid growth hormone releasing hormone therapy in healthy and laminitis-afflicted horses-evaluation and pilot study. J Gene Med 2008;10:564-574.
116. Yang PF, Hua TC, Tsung HC, Cheng QK, Cao YL. Effective cryopreservation of human embryonic stem cells by programmed freezing. Eng Med Biol Soc 2005;1:482-485.
117. Heng BC, Ye CP, Liu H, Toh WS, Rufaihah AJ, Cao T. Kinetics of cell death of frozen-chawed human embryonic stem cell colonies is reversibly slowed down by exposure to low temperature. Zygote 2006;14:341-348.
118. Attarian H, Feng Z, Buckner CD, MacLeod B, Rowley SD. Long-term cryopreservation of bone marrow for autologous transplantation. Bone Marrow Transplant 1996;17:425-430.
119. Goodwin HS, Grunzinger LM, Regan DM, et al. Long term cryostorage of UC blood units: Ability of the integral segment to confirm both identity and hematopoietic potential. Cytotherapy 2003;5:80-86.
120. Kogler G, Radke TF, Lefort A, et al. Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol 2005;33:573-583.
121. Poh KK, Sperry E, Young RG, Freyman T, Barringhaus KG, Thompson CA. Repeated direct endomyocardial transplantation of allogeneic mesenchymal stem cells: Safety of a high dose, "off-the-shelf," cellular cardiomyoplasty strategy. Int J Cardiol 2007; 117:360-364.
122. van der Laan LJ, Lockey C, Griffeth BC, et al. Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature 2000;407:90-94.
123. Nishitai R, Ikai I, Shiotani T, et al. Absence of PERV infection in baboons aftet transgenic porcine liver perfusion. J Surg Res 2005;124: 45-51.
124. Frisbie DD, Cross MW, Mcllwraith CW. A comparative study of atticular cartilage thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage thickness in the human knee. Vet Comp Orthop Traumatol 2006;19:142-146.
125. Smith RK, Webbon PM. Harnessing the stem cell for the treatment of tendon injuries: Heralding a new dawn? Br J Sports Med 2005;39:582-584.
126. Fiester A, Scholer H, Caplan A. Stem cell therapies: Time to talk to the animals. Cloning Stem Cells 2004;6:3-4.